Furthermore, SGLT2 inhibition by dapagliflozin or empagliflozin significantly reduced the risk for chronic kidney disease (CKD) progression as well as HF events in patients with CKD with or without diabetes 12. This evidence concerns the gene SLC5A2 and diabetes mellitus.